{"product_id":"srts-bcg-matrix","title":"(SRTS) Sensus Healthcare, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Sensus Healthcare, Inc. BCG Matrix helps you see how the company’s products or business units may fit into the Stars, Cash Cows, Question Marks, and Dogs framework for strategy and capital allocation. The page already contains a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSRT-100 Vision\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSRT-100 Vision is Sensus Healthcare, Inc.'s flagship SRT platform for superficial radiation therapy, and it bundles treatment planning plus embedded ultrasound imaging in 1 system.\u003c\/p\u003e\n\u003cp\u003eThat makes it the clearest growth-led product in the lineup, with a more complete workflow than basic SRT devices and stronger clinical value for skin cancer care.\u003c\/p\u003e\n\u003cp\u003eIn BCG terms, it fits the Stars bucket because it targets a growing niche and supports Sensus Healthcare, Inc.'s push for higher adoption and recurring procedure demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSRT-100 Superficial Radiation Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSRT-100 Superficial Radiation Therapy is Sensus Healthcare, Inc.’s core photon X-ray platform for low-energy superficial radiotherapy, used as a non-surgical option in skin cancer and dermatology care. It sits at the center of the revenue engine: in the latest reported year, Sensus Healthcare, Inc. generated about $33.8 million in revenue, and SRT-100 drove most system sales. Its recurring use in office-based treatment supports the cash flow profile behind the Stars label.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-frequency ultrasound imaging module\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe high-frequency ultrasound imaging module in SRT-100 Vision is a Star for Sensus Healthcare, Inc.: it adds integrated tumor visualization and margin delineation in one device. That supports treatment planning and strengthens the company’s tech edge in the skin-cancer market, where SRT-100 Vision combines imaging and therapy in a single workflow. In a niche field with a 1-device, 2-step clinical use case, this kind of integration helps defend premium positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSRT treatment planning software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSRT treatment planning software is the software layer that sets dosimetry parameters and controls workflow, so Sensus Healthcare, Inc. can make treatment more precise and easier to use. In a Stars role, it adds value by improving the user path without forcing big hardware swaps.\u003c\/p\u003e\n\u003cp\u003eThat matters because software-driven upgrades scale faster than hardware-heavy ones, and they can support new features through code changes instead of device redesign. The result is a cleaner path to broader adoption and higher repeat use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSets dosimetry and workflow\u003c\/li\u003e\n\u003cli\u003eImproves precision and usability\u003c\/li\u003e\n\u003cli\u003eSupports growth with less hardware change\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-melanoma skin cancer treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-melanoma skin cancer treatment is Sensus Healthcare’s core Stars theme because it targets basal cell and squamous cell carcinoma, the two most common skin cancers. U.S. NMSC diagnoses are estimated at 3.3 million cases a year, and the demand base is wide because dermatology practices already do high biopsy and procedure volumes. That makes the franchise tied to a large, recurring care stream.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBasal cell and squamous cell carcinoma\u003c\/li\u003e\n\u003cli\u003eLarge dermatology procedure base\u003c\/li\u003e\n\u003cli\u003eRecurring, high-volume treatment demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSensus Healthcare’s SRT-100 Powers Fast-Growing Skin-Cancer Workflow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSRT-100 Vision, SRT-100, and treatment software are Stars because they sit in Sensus Healthcare, Inc.'s fastest-adopting skin-cancer workflow and support repeat office use. In the latest reported year, Sensus Healthcare, Inc. posted about $33.8 million in revenue, with system sales led by SRT-100. The addressable base is large: U.S. non-melanoma skin cancer cases are estimated at 3.3 million a year.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSRT-100 Vision\u003c\/td\u003e\n\u003ctd\u003eIntegrated imaging plus therapy\u003c\/td\u003e\n\u003ctd\u003eSingle-device workflow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSRT-100\u003c\/td\u003e\n\u003ctd\u003eCore revenue driver\u003c\/td\u003e\n\u003ctd\u003eAbout $33.8 million revenue base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNMSC treatment\u003c\/td\u003e\n\u003ctd\u003eLarge recurring demand\u003c\/td\u003e\n\u003ctd\u003eAbout 3.3 million U.S. cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eSensus Healthcare’s BCG Matrix shows where to invest, hold, or divest across Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuick BCG snapshot of Sensus Healthcare, Inc. to pinpoint each unit fast and reduce strategy guesswork\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise source trail for Sensus Healthcare, Inc., helping verify claims quickly and strengthen investor and planning decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSentinel service program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSentinel service program is a recurring protection-and-support plan, so it generates steadier cash than a one-time system sale. For Sensus Healthcare, Inc., that makes it a classic Cash Cow in the BCG Matrix because revenue can keep flowing from the installed base with limited new-customer spend.\u003c\/p\u003e\n\u003cp\u003eThe value comes from renewal fees, not just new equipment orders, which helps smooth cash flow and support margins. In a slow-growth market, this kind of service revenue is usually more resilient than hardware demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReplacement lead shielding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReplacement lead shielding is a classic Cash Cow for Sensus Healthcare, Inc.: it is a consumable protection item sold after installation, so demand repeats as sites keep using the base system. It needs little new R\u0026amp;D, and that helps protect margin without heavy promotion spend.\u003c\/p\u003e\n\u003cp\u003eBecause the product ties to an installed base, sales are steadier than new-system orders and can lift recurring revenue. Sensus Healthcare reported $57.4 million in revenue in 2024, and this after-market line helps defend cash flow with low incremental cost.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDisposable radiation safety gear\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDisposable radiation safety gear, including aprons and eye shields, is a classic cash cow for Sensus Healthcare, Inc. because it sells again and again as treatment volume rises. These are low-ticket, recurring safety items tied to active users, so they usually bring steadier cash flow than one-time equipment sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUltrasound probe film\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltrasound probe film is a low-ticket consumable tied to imaging use, so demand repeats each time Sensus Healthcare systems run. That makes it a steady cash cow: small per unit, but sticky and replenished over time, with revenue supported by ongoing procedure volume rather than one-off hardware sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring consumable demand\u003c\/li\u003e\n\u003cli\u003eLinked to installed systems\u003c\/li\u003e\n\u003cli\u003eLow price, high repeat use\u003c\/li\u003e\n\u003cli\u003eStable add-on revenue line\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSingle-use applicator tips\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSingle-use applicator tips fit Sensus Healthcare’s installed base well: they are disposable, tied to lesion size and treatment area, and repurchased with each procedure. That makes them classic cash cows because revenue repeats as treatment volume rises, with little added complexity once the system is in place.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDisposable, procedure-linked revenue\u003c\/li\u003e\n\u003cli\u003eUsed across lesion sizes and body areas\u003c\/li\u003e\n\u003cli\u003eRepeat buys track treatment volume\u003c\/li\u003e\n\u003cli\u003eStrong installed-base cash generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSensus Healthcare’s Recurring Revenue Cash Cows Drive Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSentinel service, replacement lead shielding, and disposable safety items are Cash Cows for Sensus Healthcare, Inc. because they sell again after the system is installed, with low added cost and steady repeat demand.\u003c\/p\u003e\n\u003cp\u003eThat makes them more stable than new hardware sales and helps support cash flow as Sensus Healthcare, Inc. reported $57.4 million in 2024 revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow line\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eRevenue trait\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSentinel service\u003c\/td\u003e\n\u003ctd\u003eRecurring renewals\u003c\/td\u003e\n\u003ctd\u003eSteady\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead shielding\u003c\/td\u003e\n\u003ctd\u003eAfter-market sales\u003c\/td\u003e\n\u003ctd\u003eRepeat\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSafety consumables\u003c\/td\u003e\n\u003ctd\u003eProcedure-linked use\u003c\/td\u003e\n\u003ctd\u003eReplenished\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eSensus Healthcare, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Sensus Healthcare, Inc. BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No sample pages, no watermark, and no hidden changes—just the full, ready-to-use report. It’s formatted for clear strategic analysis and immediate practical use. Download it right after checkout and put it to work right away.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIn-office laser rentals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn-office laser rentals sit outside Sensus Healthcare, Inc.’s core sales of radiation systems, so they look more like a support service than a platform driver. The company has not broken out rental revenue as a separate 2025 line item in recent public reporting, which suggests the activity is small and not a main growth engine. In BCG terms, that weak strategic fit points to a Dog unless it proves it can scale with better margin and repeat use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy standalone SRT-100\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy standalone SRT-100 is a Dog in Sensus Healthcare, Inc.'s BCG Matrix: it is an older format without the full Vision workflow, so it lacks the integrated planning tools that buyers now expect. That raises upgrade pressure and slows new-system demand. Its share upside looks limited unless Sensus proves a clear migration path.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKeloid-only use cases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKeloid-only use cases stay a narrow dermatology niche for Sensus Healthcare, Inc. Keloids affect an estimated 4% to 16% of people, far below the broader skin cancer market, so addressable demand is small. That makes this a low-scale Dogs segment versus the company’s oncology-led uses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOne-off accessory sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOne-off accessory sales at Sensus Healthcare, Inc. are small add-ons sold outside the core system deal, so they stay fragmented and low volume. That makes them less strategic in a BCG view, because they usually add little scale or recurring revenue versus the main device business.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAd hoc, non-core revenue\u003c\/li\u003e\n\u003cli\u003eLow volume, fragmented orders\u003c\/li\u003e\n\u003cli\u003eWeak strategic weight\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSmall-site clinic deployments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSmall-site clinic deployments fit the Dogs bucket for Sensus Healthcare, Inc. because each site usually buys a narrow setup and adds little scale. Growth can stay choppy as one-location clinics face tight capex and slower approval cycles. These installs help visibility, but they rarely move company-wide volume on their own.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSingle-site demand stays limited\u003c\/li\u003e\n\u003cli\u003eBudgets are tight and uneven\u003c\/li\u003e\n\u003cli\u003eScale impact is usually low\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSensus’s “Dog” Businesses Stay Small, Niche, and Low-Fit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs in Sensus Healthcare, Inc. stay small, low-fit revenue lines: in-office laser rentals, legacy SRT-100, keloid-only use, accessory sales, and single-site clinics. The clearest signals are weak disclosure in 2025 reporting and niche demand, like keloids at 4% to 16% prevalence, which caps scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy SRT-100\u003c\/td\u003e\n\u003ctd\u003eOld, limited fit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeloid use\u003c\/td\u003e\n\u003ctd\u003e4% to 16% niche\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSRT-100 Plus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSRT-100 Plus is an added SRT-family product that can widen Sensus Healthcare, Inc.'s installed base if clinics adopt it faster. As a Question Mark, it needs proof of demand before it can scale; this matters because Sensus Healthcare, Inc. posted $0.0? No verified 2025\/2026 figures were available here. Its long-term position still depends on market acceptance and repeat placements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational market expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSensus Healthcare, Inc. sells into medical institutions worldwide, so international expansion already fits its distribution model. New-country launches can scale fast once regulators, clinics, and distributors are in place, but sales usually start from a small base. That mix of fast upside and early-stage uncertainty makes international market expansion a clear question mark in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader dermatology indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBroader dermatology uses beyond basal cell and squamous cell carcinoma could widen Sensus Healthcare, Inc.’s addressable market, but adoption still needs stronger clinician education and published evidence. Skin cancer drives over 5 million U.S. treatments a year, so even small share gains can matter. The upside is real, yet share remains uncertain until new indications show repeatable outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNew SRT-100 Vision placements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNew SRT-100 Vision placements add more sites for software, imaging, and consumables, so each sale can expand recurring revenue. In fiscal 2025, the key issue is still scale: early wins can lift adoption fast, but the base is not yet large enough to prove durable leverage.\u003c\/p\u003e\n\u003cp\u003eThis is why the product sits in Question Marks in the BCG Matrix. It has clear upside, but until repeat placements and usage rise, it stays a test case rather than a cash cow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore placements widen the installed base.\u003c\/li\u003e\n\u003cli\u003eSoftware and consumables can scale with use.\u003c\/li\u003e\n\u003cli\u003eEarly uptake can accelerate platform growth.\u003c\/li\u003e\n\u003cli\u003eScale proof is still missing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAdjacent ultrasound-guided workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdjacent ultrasound-guided workflows can expand Sensus Healthcare, Inc.'s imaging and treatment-planning use cases, but the category is still early. The technology looks promising, yet it has not scaled into a clear cash driver or market leader. That means this sits in the Question Marks box: it needs more spend, proof, and adoption before it can move toward a winner.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWider workflow use can lift demand\u003c\/li\u003e\n\u003cli\u003eScale is still limited today\u003c\/li\u003e\n\u003cli\u003eMore investment is needed first\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSensus’ Question Marks: Small Scale, Big Recurring Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks at Sensus Healthcare, Inc. are mainly new SRT placements and adjacent uses: they can lift recurring software and consumable sales, but 2025 scale is still too small to prove durable pull-through. U.S. skin cancer treatments top 5 million a year, so even modest share gains matter, but adoption and repeat use remain the test.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. skin cancer treatments\u003c\/td\u003e\n\u003ctd\u003e5M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore issue\u003c\/td\u003e\n\u003ctd\u003eScale proof\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpside\u003c\/td\u003e\n\u003ctd\u003eRecurring revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234941116681,"sku":"srts-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/srts-bcg-matrix.webp?v=1785732491","url":"https:\/\/dcfanalyst.com\/products\/srts-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}